Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Citation: Boominathan, Interleukin-based therapy for Fibrosis: IL-1β suppresses the expression of TGFß receptor II (TGFBR2) and extracellular matrix proteins via up regulation of its target gene, 25/October/2014, 10.44 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Significance: This study suggests that IL-1β, by increasing the expression of its target gene, it may decrease the expression of TGFß receptor II (TGFBR2) and extracellular matrix proteins. Thus, pharmacological formulations encompassing “IL-1β activators“ may be used to treat fibrosis.
Amount: $300
Undisclosed information: An insight into how IL-1β suppresses the expression of TGFß receptor II (TGFBR2) and extracellular matrix proteins.
Courtesy: When you cite drop us a line at info@genomediscovery.org
Web: http://genomediscovery.org
